25 November 2019 | News
First-of-its kind smart device launched in India to track usage pattern of metered dose inhaler (MDI) by patients
Pharma major Lupin Limited (Lupin) announced the launch of “ADHERO,” a new connected smart device for metered-dose inhalers. This first-of-its-kind device is designed to help patients with chronic respiratory diseases track their MDI usage and facilitate improved adherence to therapy.
Inhalers are the preferred treatment option for managing the rising incidence of Chronic respiratory diseases like Asthma and COPD in India.
However, it is estimated that nearly 45 percent patients do not adhere to therapy (in terms of filling / refilling prescriptions or maintaining prescribed medication schedule), which adversely impacts clinical outcomes and patient quality of life. The new device, ADHERO, is designed to improve patient adherence to therapy.
Lupin has collaborated with Aptar Pharma, a leading provider of drug delivery devices, components and services in bringing this first in class device to market.
ADHERO is a bluetooth-enabled, reusable smart device which attaches to the top of a MDI. With built-in sensors, the device tracks the patient’s daily medication usage and consumption patterns. Patients can access this information by connecting their ADHERO device to the “MyAdhero” app on their smartphones.
The app is also equipped to send reminders, provide contextual health alerts based on factors like Air Quality Index (AQI) at the patient’s current location and enable visual analytics. Physicians too can access patient-related information and medication tracking data through the patient dashboard portal as well as through the app.
Speaking on the launch, Rajeev Sibal, President India Region Formulations, Lupin Limited, said, “Lupin lays great emphasis on three aspects of Respiratory Medicine, namely Disease Awareness, Diagnosis and Adherence. The launch of ADHERO will be a great help to patients using metered dose inhalers, as well as, for Doctors to track adherence and compliance to therapy, thereby improving clinical outcomes and quality of life of patients.”